Predicting the response of CML patients to tyrosine kinase inhibitor therapy

Current Hematologic Malignancy Reports

Volumn 4, Issue 2, 2009, Pages 59-65

  White, Deborah L ^a   Hughes, Timothy P ^a  

^a INSTITUTE OF MEDICAL AND VETERINARY SCIENCE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; IMATINIB; ORGANIC CATION TRANSPORTER 1; PROTEIN TYROSINE KINASE INHIBITOR; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; WILMS CANCER PROTEIN 1;

CANCER SURVIVAL; CHROMOSOME 9; CHROMOSOME DELETION; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CHOICE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG METABOLISM; DRUG TARGETING; DRUG TRANSPORT; DRUG UPTAKE; GENE ACTIVITY; GENE EXPRESSION; HUMAN; IC 50; MONOTHERAPY; PROGNOSIS; REVIEW; SURVIVAL RATE; TARGET CELL DESTRUCTION; TREATMENT DURATION; TREATMENT RESPONSE;

DISEASE PROGRESSION; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; ORGANIC CATION TRANSPORTER 1; PROGNOSIS; PROTEIN KINASE INHIBITORS; TREATMENT OUTCOME; WT1 PROTEINS;

EID: 63549148813     PISSN: 15588211     EISSN: 1558822X     Source Type: Journal    
DOI: 10.1007/s11899-009-0009-2     Document Type: Review

References (52)

1. Groffen J, Stephenson JR, Heisterkamp N, et al.: Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22. Cell 1984, 36:93-99.
2. Heisterkamp N, Groffen J, Stephenson JR, et al.: Chromosomal localization of human cellular homologues of two viral oncogenes. Nature 1982, 299:747-749.
3. de Klein A, van Kessel AG, Grosveld G, et al.: A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia. Nature 1982, 300:765-767.
4. Daley GQ, Van Etten RA, Baltimore D: Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science 1990, 247:824-830.
5. Daley GQ, Baltimore D: Transformation of an interleukin 3-dependent hematopoietic cell line by the chronic myelogenous leukemia-specific P210bcr/abl protein. Proc Natl Acad Sci U S A 1988, 85:9312-9316.
6. Lugo TG, Pendergast AM, Muller AJ, Witte ON: Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science 1990, 247:1079-1082.
7. Buchdunger E, Zimmermann J, Mett H, et al.: Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res 1996, 56:100-104.
8. Druker BJ, Sawyers CL, Kantarjian H, et al.: Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001, 344:1038-1042.
9. Druker BJ, Talpaz M, Resta DJ, et al.: Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001, 344:1031-1037.
10. O'Brien SG, Guilhot F, Larson RA, et al.: Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003, 348:994-1004.
11. Branford S, Rudzki Z, Harper A, et al.: Imatinib produces significantly superior molecular responses compared to interferon alfa plus cytarabine in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Leukemia 2003, 17:2401-2409.
12. Baccarani M, Saglio G, Goldman J, et al.: Evolving concepts in the management of chronic myeloid leukemia: Recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2006, 108:1809-1820.
13. Sokal JE, Cox EB, Baccarani M, et al.: Prognostic discrimination in "good-risk" chronic granulocytic leukemia. Blood 1984, 63:789-799.
14. Hasford J, Pfirrmann M, Hehlmann R, et al.: A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group. J Natl Cancer Inst 1998, 90:850-858.
15. Cortes J, Talpaz M, O'Brien S, et al.: Effects of age on prognosis with imatinib mesylate therapy for patients with Philadelphia chromosome-positive chronic myelogenous leukemia. Cancer 2003, 98:1105-1113.
16. Hasford J, Pfirrmann M, Hehlmann R, et al.: Prognosis and prognostic factors for patients with chronic myeloid leukemia: Nontransplant therapy. Semin Hematol 2003, 40:4-12.
17. Hehlmann R, Heimpel H, Hasford J, et al.: Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia. The German CML Study Group. Blood 1994, 84:4064-4077.
18. Cervantes F, Hernandez-Boluda JC, Steegmann JL, et al.: Imatinib mesylate therapy of chronic phase chronic myeloid leukemia resistant or intolerant to interferon: Results and prognostic factors for response and progression-free survival in 150 patients. Haematologica 2003, 88:1117-1122.
19. Hughes TP, Kaeda J, Branford S, et al.: Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 2003, 349:1423-1432.
20. Huntly BJ, Bench A, Green AR. Double jeopardy from a single translocation: Deletions of the derivative chromosome 9 in chronic myeloid leukemia. Blood 2003, 102:1160-1168.
21. Sinclair PB, Nacheva EP, Leversha M, et al.: Large deletions at the t(9, 22) breakpoint are common and may identify a poor-prognosis subgroup of patients with chronic myeloid leukemia. Blood 2000, 95:738-743.
22. Herens C, Tassin F, Lemaire V, et al.: Deletion of the 5′-ABL region: A recurrent anomaly detected by fluorescence in situ hybridization in about 10% of Philadelphia-positive chronic myeloid leukaemia patients. Br J Haematol 2000, 110:214-216.
23. Huntly BJ, Guilhot F, Reid AG, et al.: Imatinib improves but may not fully reverse the poor prognosis of patients with CML with derivative chromosome 9 deletions. Blood 2003, 102:2205-2212.
24. Quintas-Cardama A, Kantarjian H, Talpaz M, et al.: Imatinib mesylate therapy may overcome the poor prognostic significance of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia. Blood 2005, 105:2281-2286.
25. Loncarevic IF, Romer J, Starke H, et al.: Heterogenic molecular basis for loss of ABL1-BCR transcription: Deletions in der(9)t(9, 22) and variants of standard t(9, 22) in BCR-ABL1-positive chronic myeloid leukemia. Genes Chromosomes Cancer 2002, 34:193-200.
26. Potter AM, Watmore AE, Cooke P, et al.: Significance of non-standard Philadelphia chromosomes in chronic granulocytic leukaemia. Br J Cancer 1981, 44:51-54.
27. Reid AG, Huntly BJ, Grace C, et al.: Survival implications of molecular heterogeneity in variant Philadelphia-positive chronic myeloid leukaemia. Br J Haematol 2003, 121:419-427.
28. El-Zimaity MM, Kantarjian H, Talpaz M, et al.: Results of imatinib mesylate therapy in chronic myelogenous leukaemia with variant Philadelphia chromosome. Br J Haematol 2004, 125:187-195.
29. Kantarjian HM, Talpaz M, O'Brien S, et al.: Imatinib mesylate for Philadelphia chromosome-positive, chronicphase myeloid leukemia after failure of interferon-alpha: Follow-up results. Clin Cancer Res 2002, 8:2177-2187.
30. Marin D, Marktel S, Bua M, et al.: Prognostic factors for patients with chronic myeloid leukaemia in chronic phase treated with imatinib mesylate after failure of interferon alfa. Leukemia 2003, 17:1448-1453.
31. Kantarjian H, Cortes J: Testing the prognostic model of Marin et al in an independent chronic myelogenous leukemia study group. Leukemia 2004, 18:650.
32. Hochhaus A, Kreil S, Corbin AS, et al.: Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia 2002, 16:2190-2196.
33. White D, Saunders V, Lyons AB, et al.: In vitro sensitivity to imatinib-induced inhibition of ABL kinase activity is predictive of molecular response in patients with de novo CML. Blood 2005, 106:2520-2526.
34. Thomas J, Wang L, Clark RE, Pirmohamed M: Active transport of imatinib into and out of cells: Implications for drug resistance. Blood 2004, 104:3739-3745.
35. Crossman LC, Druker BJ, Deininger MW, et al.: HOCT 1 and resistance to imatinib [comment]. Blood 2005, 106:1133-1134, author reply 1134.
36. Wang L, Giannoudis A, Lane S, et al.: Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia. Clin Pharmacol Ther 2008, 83:258-264.
37. White DL, Saunders VA, Dang P, et al.: Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: Higher doses of imatinib may overcome the negative impact of low OCT-1 activity. Blood 2007, 110:4064-4072.
38. Koepsell H, Schmitt BM, Gorboulev V: Organic cation transporters. Rev Physiol Biochem Pharmacol 2003, 150:36-90.
39. Kantarjian HM, Cortes JE, O'Brien S, et al.: Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferon-{alpha}. Blood 2004, 104:1979-1988.
40. Call KM, Glaser T, Ito CY, et al.: Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms' tumor locus. Cell 1990, 60:509-520.
41. Cilloni D, Gottardi E, De Micheli D, et al.: Quantitative assessment of WT1 expression by real time quantitative PCR may be a useful tool for monitoring minimal residual disease in acute leukemia patients. Leukemia 2002, 16:2115-2121.
42. Cilloni D, Messa F, Gottardi E, et al.: Sensitivity to imatinib therapy may be predicted by testing Wilms tumor gene expression and colony growth after a short in vitro incubation. Cancer 2004, 101:979-988.
43. Picard S, Titier K, Etienne G, et al.: Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood 2007, 109:3496-3499.
44. Larson RA, Druker BJ, Guilhot F, et al.: Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: A subanalysis of the IRIS study. Blood 2008, 111:4022-4028.
45. Hughes T, Branford S: Molecular monitoring of chronic myeloid leukemia. Semin Hematol 2003, 40(2 Suppl 3):62-68.
46. White D, Saunders V, Grigg A, et al.: Measurement of in vivo BCR-ABL kinase inhibition to monitor imatinib-induced target blockade and predict response in chronic myeloid leukemia. J Clin Oncol 2007, 25:4445-4451.
47. O'Hare T, Walters DK, Stoffregen EP, et al.: In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res 2005, 65:4500-4505.
48. Weisberg E, MaAley P, Mestan J, et al.: AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL. Br J Cancer 2006, 94:1765-1769.
49. Weisberg E, Manley PW, Breitenstein W, et al.: Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 2005, 7:129-141.
50. White DL, Saunders VA, Dang P, et al.: OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): Reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib. Blood 2006, 108:697-704.
51. Hiwase DK, Saunders V, Hewett D, et al.: Dasatinib cellular uptake and efflux in chronic myeloid leukemia cells: Therapeutic implications. Clin Cancer Res 2008, 14:3881-3888.
52. Giannoudis A, Davies A, Lucas CM, et al.: Effective dasatinib uptake may occur without human organic cation transporter 1 (hOCT1): Implications for the treatment of imatinib-resistant chronic myeloid leukemia. Blood 2008, 112:3348-3354.